PP242 suppresses bladder cancer cell proliferation and migration through deactivating the mammalian target of rapamycin complex 2/AKT1 signaling pathway

Zhang,Zhe; Zhang,Guojun; Kong,Chuize; Gong,Daxin

doi:10.3892/mmr.2015.4528

PP242 suppresses bladder cancer cell proliferation and migration through deactivating the mammalian target of rapamycin complex 2/AKT1 signaling pathway

Authors:
- Zhe Zhang
- Guojun Zhang
- Chuize Kong
- Daxin Gong
View Affiliations

Affiliations: Department of Urology, The First Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China, Department of Hematology, Shengjing Hospital of China Medical University, Shenyang, Liaoning 110022, P.R. China
Published online on: November 6, 2015 https://doi.org/10.3892/mmr.2015.4528
Pages: 333-338

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

While most cancer types are resistant to mammalian target of rapamycin complex 1 (mTORC1) inhibitor rapamycin, recent studies have identified mTORC2 as an important prospective therapeutic target for cancer. The present study assessed the effects of mTORC2 inhibitor PP242 on the proliferation and migration of bladder cancer cells by using Cell Counting Kit‑8, 5‑ethynyl‑2'‑deoxyuridine incorporation, wound healing and Transwell assays. Furthermore, the phosphorylation status of downstream signaling proteins of mTORC1 and mTORC2 was assessed using western blot analysis. The results demonstrated that PP242 concentration‑dependently inhibited the proliferation of bladder cancer cells. Simultaneously, the migration ability of bladder cancer cells was suppressed by PP242. In addition, PP242 markedly restrained the phosphorylation of AKT1 and mTORC2, while the phosphorylation status of S6K1 and mTORC1 was not affected. These results suggested that PP242 exerts potent inhibitory effects on bladder cancer cells by modulating the activity of the mTORC2/AKT1 pathway.

View Figures

View References

1	Zuo W, Wang ZZ and Xue J: Artesunate induces apoptosis of bladder cancer cells by miR-16 regulation of COX-2 expression. Int J Mol Sci. 15:14298–14312. 2014. View Article : Google Scholar : PubMed/NCBI
2	Chang H, Peng X, Bai Q, Zhou Y, Yu X, Zhang Q, Zhu J and Mi M: Ampelopsin suppresses breast carcinogenesis by inhibiting the mTOR signaling pathway. Carcinogenesis. 35:1847–1854. 2014. View Article : Google Scholar : PubMed/NCBI
3	Rivas DA, Yaspelkis BB III, Hawley JA and Lessard SJ: Lipid-induced mTOR activation in rat skeletal muscle reversed by exercise and 5′-aminoimidazole-4-carboxamide-1-beta -D-ribofuranoside. J Endocrinol. 202:441–451. 2009. View Article : Google Scholar : PubMed/NCBI
4	Wahane SD, Hellbach N, Prentzell MT, Weise SC, Vezzali R, Kreutz C, Timmer J, Krieglstein K, Thedieck K and Vogel T: PI3K-p110-alpha-subtype signalling mediates survival, proliferation and neurogenesis of cortical progenitor cells via activation of mTORC2. J Neurochem. 130:255–267. 2014. View Article : Google Scholar : PubMed/NCBI
5	Zhang Z, Zhang G, Xu X, Su W and Yu B: MTOR-rictor is the Ser473 kinase for AKT1 in mouse one-cell stage embryos. Mol Cell Biochem. 361:249–257. 2012. View Article : Google Scholar
6	Jash S, Dhar G, Ghosh U and Adhya S: Role of the mTORC1 complex in satellite cell activation by RNA-induced mitochondrial restoration: Dual control of cyclin D1 through microRNAs. Mol Cell Biol. 34:3594–3606. 2014. View Article : Google Scholar : PubMed/NCBI
7	Goodman CA: The role of mTORC1 in regulating protein synthesis and skeletal muscle mass in response to various mechanical stimuli. Rev Physiol Biochem Pharmacol. 166:43–95. 2014.PubMed/NCBI
8	Faller WJ, Jackson TJ, Knight JR, Ridgway RA, Jamieson T, Karim SA, Jones C, Radulescu S, Huels DJ, Myant KB, et al: MTORC1-mediated translational elongation limits intestinal tumour initiation and growth. Nature. 517:497–500. 2015. View Article : Google Scholar :
9	Kaibori M, Shikata N, Sakaguchi T, Ishizaki M, Matsui K, Iida H, Tanaka Y, Miki H, Nakatake R, Okumura T, et al: Influence of rictor and raptor expression of mtor signaling on long-term outcomes of patients with hepatocellular carcinoma. Dig Dis Sci. 60:919–928. 2015. View Article : Google Scholar
10	Randall JM, Millard F and Kurzrock R: Molecular aberrations, targeted therapy and renal cell carcinoma: Current state-of-the-art. Cancer Metastasis Rev. 33:1109–1124. 2014. View Article : Google Scholar : PubMed/NCBI
11	Treilleux I, Arnedos M, Cropet C, Wang Q, Ferrero JM, Abadie-Lacourtoisie S, Levy C, Legouffe E, Lortholary A, Pujade-Lauraine E, et al: Translational studies within the TAMRAD randomized GINECO trial: Evidence for mTORC1 activation marker as a predictive factor for everolimus efficacy in advanced breast cancer. Ann Oncol. 26:120–125. 2015. View Article : Google Scholar
12	Sandhöfer N, Metzeler KH, Rothenberg M, Herold T, Tiedt S, Groiß V, Carlet M, Walter G, Hinrichsen T, Wachter O, et al: Dual PI3 K/mTOR inhibition shows antileukemic activity in MLL rearranged acute myeloid leukemia. Leukemia. 29:828–838. 2015. View Article : Google Scholar
13	Yue H, Li W, Liu P, Gao J, Miao J and Zhao J: Inhibition of autophagy promoted sphingosylphosphorylcholine induced cell death in non-small cell lung cancer cells. Biochem Biophys Res Commun. 453:502–507. 2014. View Article : Google Scholar : PubMed/NCBI
14	Joha S, Nugues AL, Hétuin D, Berthon C, Dezitter X, Dauphin V, Mahon FX, Roche-Lestienne C, Preudhomme C, Quesnel B and Idziorek T: GILZ inhibits the mTORC2/AKT pathway in BCR-ABL(+) cells. Oncogene. 31:1419–1430. 2012. View Article : Google Scholar :
15	Zheng X, Liang Y, He Q, Yao R, Bao W, Bao L, Wang Y and Wang Z: Current models of mammalian target of rapamycin complex 1 (mTORC1) activation by growth factors and amino acids. Int J Mol Sci. 15:20753–20769. 2014. View Article : Google Scholar : PubMed/NCBI
16	Huang Y, Xi Q, Chen Y, Wang J, Peng P, Xia S and Yu S: A dual mTORC1 and mTORC2 inhibitor shows antitumor activity in esophageal squamous cell carcinoma cells and sensitizes them to cisplatin. Anticancer Drugs. 24:889–898. 2013. View Article : Google Scholar : PubMed/NCBI
17	Zhang Z, Zhang G and Kong C: High expression of Cdc25B and low expression of 14-3-3σ is associated with the development and poor prognosis in urothelial carcinoma of bladder. Tumour Biol. 35:2503–2512. 2014. View Article : Google Scholar
18	Fan W, Cheng K, Qin X, Narsinh KH, Wang S, Hu S, Wang Y, Chen Y, Wu JC, Xiong L and Cao F: MTORC1 and mTORC2 play different roles in the functional survival of transplanted adipose-derived stromal cells in hind limb ischemic mice via regulating inflammation in vivo. Stem Cells. 31:203–214. 2013. View Article : Google Scholar
19	Baack Kukreja JE, Scosynev E, Brasachio RA, Toy EP, Messing EM and Wu G: Bladder cancer incidence and mortality in patients treated with radiation for uterine cancer. BJU Int. 114:844–851. 2014. View Article : Google Scholar
20	Kamat AM, Vlahou A, Taylor JA, Hudson ML, Pesch B, Ingersoll MA, Todenhöfer T, van Rhijn B, Kassouf W, Barton Grossman H, et al: Considerations on the use of urine markers in the management of patients with high-grade non-muscle-invasive bladder cancer. Urol Oncol. 32:1069–1077. 2014. View Article : Google Scholar : PubMed/NCBI
21	Petrelli F, Coinu A, Cabiddu M, Ghilardi M, Vavassori I and Barni S: Correlation of pathologic complete response with survival after neoadjuvant chemotherapy in bladder cancer treated with cystectomy: A meta-analysis. Eur Urol. 65:350–357. 2014. View Article : Google Scholar
22	Xing X, Zhang L, Wen X, Wang X, Cheng X, Du H, Hu Y, Li L, Dong B, Li Z and Ji J: PP242 suppresses cell proliferation, metastasis and angiogenesis of gastric cancer through inhibition of the PI3K/AKT/mTOR pathway. Anticancer Drugs. 25:1129–1140. 2014. View Article : Google Scholar : PubMed/NCBI
23	Korets SB, Musa F, Curtin J, Blank SV and Schneider RJ: Dual mTORC1/2 inhibition in a preclinical xenograft tumor model of endometrial cancer. Gynecol Oncol. 132:468–473. 2014. View Article : Google Scholar
24	Zhou HY and Huang SL: Current development of the second generation of mTOR inhibitors as anticancer agents. Chin J Cancer. 31:8–18. 2012.
25	Chen L, Xu B, Liu L, Liu C, Luo Y, Chen X, Barzegar M, Chung J and Huang S: Both mTORC1 and mTORC2 are involved in the regulation of cell adhesion. Oncotarget. 30:7136–7150. 2015. View Article : Google Scholar
26	Ravichandran K, Zafar I, Ozkok A and Edelstein CL: An mTOR kinase inhibitor slows disease progression in a rat model of poly-cystic kidney disease. Nephrol Dial Transplant. 30:45–53. 2015. View Article : Google Scholar
27	Qin Y, Zhao X and Fang Y: PP242 synergizes with suberoylanilide hydroxamic acid to inhibit growth of ovarian cancer cells. Int J Gynecol Cancer. 24:1373–1380. 2014. View Article : Google Scholar : PubMed/NCBI
28	Goncharov DA, Kudryashova TV, Ziai H, Ihida-Stansbury K, DeLisser H, Krymskaya VP, Tuder RM, Kawut SM and Goncharova EA: Mammalian target of rapamycin complex 2 (mTORC2) coordinates pulmonary artery smooth muscle cell metabolism, proliferation and survival in pulmonary arterial hypertension. Circulation. 129:864–874. 2014. View Article : Google Scholar :
29	Becker MN, Wu KJ, Marlow LA, Kreinest PA, Vonroemeling CA, Copland JA and Williams CR: The combination of an mTORc1/TORc2 inhibitor with lapatinib is synergistic in bladder cancer in vitro. Urol Oncol. 32:317–326. 2014. View Article : Google Scholar
30	Bogani C, Bartalucci N, Martinelli S, Tozzi L, Guglielmelli P, Bosi A and Vannucchi AM; Associazione Italiana per la Ricerca sul Cancro AGIMM Gruppo Italiano Malattie Mieloproliferative: MTOR inhibitors alone and in combination with JAK2 inhibitors effectively inhibit cells of myeloproliferative neoplasms. PLoS One. 8:e548262013. View Article : Google Scholar : PubMed/NCBI
31	Müller J, Ehlers A, Burkhardt L, Sirma H, Steuber T, Graefen M, Sauter G, Minner S, Simon R, Schlomm T and Michl U: Loss of pSer2448-mTOR expression is linked to adverse prognosis and tumor progression in ERG-fusion-positive cancers. Int J Cancer. 132:1333–1340. 2013. View Article : Google Scholar
32	Vazquez-Martin A, Oliveras-Ferraros C, Bernadó L, López-Bonet E and Menendez JA: The serine 2481-autophos-phorylated form of mammalian Target of Rapamycin (mTOR) is localized to midzone and midbody in dividing cancer cells. Biochem Biophys Res Commun. 380:638–643. 2009. View Article : Google Scholar : PubMed/NCBI
33	Wang X, Lai P, Zhang Z, Huang M, Wang L, Yin M, Jin D, Zhou R and Bai X: Targeted inhibition of mTORC2 prevents osteosarcoma cell migration and promotes apoptosis. Oncol Rep. 32:382–388. 2014.PubMed/NCBI
34	Li H, Lin J, Wang X, Yao G, Wang L, Zheng H, Yang C, Jia C, Liu A and Bai X: Targeting of mTORC2 prevents cell migration and promotes apoptosis in breast cancer. Breast Cancer Res Treat. 134:1057–1066. 2012. View Article : Google Scholar : PubMed/NCBI